O	0	6	Twenty
O	6	7	-
O	7	11	year
O	12	18	follow
O	18	19	-
O	19	21	up
O	22	24	of
O	25	28	the
O	29	34	Royal
O	35	42	Marsden
O	43	53	randomized
O	53	54	,
O	55	61	double
O	61	62	-
O	62	69	blinded
B-intervention	70	79	tamoxifen
O	80	86	breast
O	87	93	cancer
O	94	104	prevention
O	105	110	trial
O	110	111	.

O	112	119	Several
O	120	128	clinical
O	129	135	trials
O	136	140	have
O	141	149	reported
O	150	152	an
O	153	158	early
O	159	168	reduction
O	169	171	in
O	172	178	breast
O	179	185	cancer
O	186	195	incidence
O	196	198	in
O	199	206	healthy
O	207	212	women
O	213	218	using
O	219	228	tamoxifen
O	229	231	to
O	232	238	reduce
O	239	244	their
O	245	249	risk
O	250	252	of
O	253	259	breast
O	260	266	cancer
O	267	270	but
O	271	275	have
O	276	279	not
O	280	288	reported
O	289	295	longer
O	296	302	follow
O	302	303	-
O	303	305	up
O	306	310	data
O	311	314	for
O	315	318	the
O	319	329	evaluation
O	330	332	of
O	333	339	breast
O	340	346	cancer
O	347	357	prevention
O	357	358	.

O	359	361	We
O	362	368	report
O	369	372	the
O	373	380	blinded
O	381	383	20
O	383	384	-
O	384	388	year
O	389	395	follow
O	395	396	-
O	396	398	up
O	399	400	(
O	400	406	median
O	407	413	follow
O	413	414	-
O	414	416	up
O	417	418	=
O	419	421	13
O	422	427	years
O	427	428	)
O	429	431	of
O	432	435	the
O	436	441	Royal
O	442	449	Marsden
O	450	455	trial
O	456	458	to
O	459	467	identify
O	468	471	any
O	472	476	long
O	476	477	-
O	477	481	term
O	482	492	prevention
O	493	495	of
O	496	502	breast
O	503	509	cancer
O	510	520	associated
O	521	525	with
O	526	535	tamoxifen
O	536	545	treatment
O	545	546	.

O	547	549	We
O	550	558	randomly
O	559	567	assigned
B-total-participants	568	572	2494
B-eligibility	573	580	healthy
I-eligibility	581	586	women
O	587	589	to
O	590	594	oral
O	595	604	tamoxifen
O	605	606	(
O	606	608	20
O	609	611	mg
O	611	612	/
O	612	615	day
O	615	616	)
O	617	619	or
B-control	620	627	placebo
O	628	631	for
O	632	633	8
O	634	639	years
O	639	640	.

O	641	644	The
O	645	652	primary
O	653	660	outcome
O	661	664	was
B-outcome-Measure	665	675	occurrence
I-outcome-Measure	676	678	of
I-outcome-Measure	679	687	invasive
I-outcome-Measure	688	694	breast
I-outcome-Measure	695	701	cancer
O	701	702	.

O	703	704	A
O	705	714	secondary
O	715	722	planned
O	723	731	analysis
O	732	734	of
B-outcome-Measure	735	743	estrogen
I-outcome-Measure	744	752	receptor
I-outcome-Measure	753	754	(
I-outcome-Measure	754	756	ER
I-outcome-Measure	756	757	)
I-outcome-Measure	757	758	-
I-outcome-Measure	758	766	positive
I-outcome-Measure	767	775	invasive
I-outcome-Measure	776	782	breast
I-outcome-Measure	783	789	cancer
O	790	793	was
O	794	798	also
O	799	803	done
O	803	804	.

O	805	813	Survival
O	814	817	was
O	818	826	assessed
O	827	829	by
O	830	833	use
O	834	836	of
O	837	838	a
O	839	842	Cox
O	843	855	proportional
O	856	863	hazards
O	864	869	model
O	870	872	in
O	873	877	both
O	878	888	univariate
O	889	892	and
O	893	906	multivariable
O	907	915	analyses
O	915	916	.

O	917	920	The
O	921	931	durability
O	932	934	of
O	935	938	the
O	939	948	treatment
O	949	955	effect
O	956	959	was
O	960	968	assessed
O	969	971	by
O	972	975	use
O	976	978	of
O	979	980	a
O	981	984	Cox
O	985	995	regression
O	996	1004	analysis
O	1004	1005	.

O	1006	1009	All
O	1010	1021	statistical
O	1022	1027	tests
O	1028	1032	were
O	1033	1036	two
O	1036	1037	-
O	1037	1042	sided
O	1042	1043	.

O	1044	1049	Among
O	1050	1053	the
B-total-participants	1054	1058	2471
O	1059	1067	eligible
O	1068	1080	participants
O	1081	1082	(
B-intervention-participants	1082	1086	1238
O	1087	1099	participants
O	1100	1102	in
O	1103	1106	the
O	1107	1116	tamoxifen
O	1117	1120	arm
O	1121	1124	and
B-control-participants	1125	1129	1233
O	1130	1142	participants
O	1143	1145	in
O	1146	1149	the
O	1150	1157	placebo
O	1158	1161	arm
O	1161	1162	)
O	1162	1163	,
O	1164	1167	186
O	1168	1177	developed
B-outcome	1178	1186	invasive
I-outcome	1187	1193	breast
I-outcome	1194	1200	cancer
O	1201	1202	(
B-iv-bin-abs	1202	1204	82
O	1205	1207	on
O	1208	1217	tamoxifen
O	1218	1221	and
B-cv-bin-abs	1222	1225	104
O	1226	1228	on
O	1229	1236	placebo
O	1236	1237	;
O	1238	1244	hazard
O	1245	1250	ratio
O	1251	1252	[
O	1252	1254	HR
O	1254	1255	]
O	1256	1257	=
O	1258	1259	0
O	1259	1260	.
O	1260	1262	78
O	1262	1263	,
O	1264	1266	95
O	1266	1267	%
O	1268	1278	confidence
O	1279	1287	interval
O	1288	1289	[
O	1289	1291	CI
O	1291	1292	]
O	1293	1294	=
O	1295	1296	0
O	1296	1297	.
O	1297	1299	58
O	1300	1302	to
O	1303	1304	1
O	1304	1305	.
O	1305	1307	04
O	1307	1308	;
O	1309	1310	P
O	1311	1312	=
O	1313	1314	.
O	1314	1315	1
O	1315	1316	)
O	1316	1317	.

O	1318	1320	Of
O	1321	1326	these
O	1327	1330	186
O	1331	1338	cancers
O	1338	1339	,
O	1340	1343	139
O	1344	1348	were
B-outcome	1349	1351	ER
I-outcome	1352	1360	positive
O	1361	1362	(
B-iv-bin-abs	1362	1364	53
O	1365	1367	on
O	1368	1377	tamoxifen
O	1378	1381	and
B-cv-bin-abs	1382	1384	86
O	1385	1387	on
O	1388	1395	placebo
O	1395	1396	;
O	1397	1399	HR
O	1400	1401	=
O	1402	1403	0
O	1403	1404	.
O	1404	1406	61
O	1406	1407	,
O	1408	1410	95
O	1410	1411	%
O	1412	1414	CI
O	1415	1416	=
O	1417	1418	0
O	1418	1419	.
O	1419	1421	43
O	1422	1424	to
O	1425	1426	0
O	1426	1427	.
O	1427	1429	86
O	1429	1430	;
O	1431	1432	P
O	1433	1434	=
O	1435	1436	.
O	1436	1439	005
O	1439	1440	)
O	1440	1441	.

O	1442	1445	The
B-outcome	1446	1450	risk
I-outcome	1451	1453	of
I-outcome	1454	1456	ER
I-outcome	1456	1457	-
I-outcome	1457	1465	positive
I-outcome	1466	1472	breast
I-outcome	1473	1479	cancer
O	1480	1483	was
O	1484	1487	not
O	1488	1501	statistically
O	1502	1515	significantly
O	1516	1521	lower
O	1522	1524	in
O	1525	1528	the
O	1529	1538	tamoxifen
O	1539	1542	arm
O	1543	1547	than
O	1548	1550	in
O	1551	1554	the
O	1555	1562	placebo
O	1563	1566	arm
O	1567	1573	during
O	1574	1577	the
O	1578	1579	8
O	1579	1580	-
O	1580	1584	year
O	1585	1594	treatment
O	1595	1601	period
O	1602	1603	(
B-iv-bin-abs	1603	1605	30
O	1606	1613	cancers
O	1614	1616	in
O	1617	1620	the
O	1621	1630	tamoxifen
O	1631	1634	arm
O	1635	1638	and
B-cv-bin-abs	1639	1641	39
O	1642	1644	in
O	1645	1648	the
O	1649	1656	placebo
O	1657	1660	arm
O	1660	1661	;
O	1662	1664	HR
O	1665	1666	=
O	1667	1668	0
O	1668	1669	.
O	1669	1671	77
O	1671	1672	,
O	1673	1675	95
O	1675	1676	%
O	1677	1679	CI
O	1680	1681	=
O	1682	1683	0
O	1683	1684	.
O	1684	1686	48
O	1687	1689	to
O	1690	1691	1
O	1691	1692	.
O	1692	1694	23
O	1694	1695	;
O	1696	1697	P
O	1698	1699	=
O	1700	1701	.
O	1701	1702	3
O	1702	1703	)
O	1704	1707	but
O	1708	1711	was
O	1712	1725	statistically
O	1726	1739	significantly
O	1740	1745	lower
O	1746	1748	in
O	1749	1752	the
B-outcome	1753	1766	posttreatment
I-outcome	1767	1773	period
O	1774	1775	(
B-iv-bin-abs	1775	1777	23
O	1778	1780	in
O	1781	1784	the
O	1785	1794	tamoxifen
O	1795	1798	arm
O	1799	1802	and
B-cv-bin-abs	1803	1805	47
O	1806	1808	in
O	1809	1812	the
O	1813	1820	placebo
O	1821	1824	arm
O	1824	1825	;
O	1826	1828	HR
O	1829	1830	=
O	1831	1832	0
O	1832	1833	.
O	1833	1835	48
O	1835	1836	,
O	1837	1839	95
O	1839	1840	%
O	1841	1843	CI
O	1844	1845	=
O	1846	1847	0
O	1847	1848	.
O	1848	1850	29
O	1851	1853	to
O	1854	1855	0
O	1855	1856	.
O	1856	1858	79
O	1858	1859	;
O	1860	1861	P
O	1862	1863	=
O	1864	1865	.
O	1865	1868	004
O	1868	1869	)
O	1869	1870	.

B-iv-bin-abs	1871	1876	Fifty
I-iv-bin-abs	1876	1877	-
I-iv-bin-abs	1877	1881	four
O	1882	1894	participants
O	1895	1897	in
O	1898	1902	each
O	1903	1906	arm
O	1907	1911	have
B-outcome	1912	1916	died
O	1917	1921	from
O	1922	1925	any
O	1926	1931	cause
O	1932	1933	(
O	1933	1935	HR
O	1936	1937	=
O	1938	1939	0
O	1939	1940	.
O	1940	1942	99
O	1942	1943	,
O	1944	1946	95
O	1946	1947	%
O	1948	1950	CI
O	1951	1952	=
O	1953	1954	0
O	1954	1955	.
O	1955	1957	68
O	1958	1960	to
O	1961	1962	1
O	1962	1963	.
O	1963	1965	44
O	1965	1966	;
O	1967	1968	P
O	1969	1970	=
O	1971	1972	.
O	1972	1974	95
O	1974	1975	)
O	1975	1976	.

O	1977	1980	The
B-outcome	1981	1988	adverse
I-outcome	1989	1994	event
I-outcome	1995	2003	profiles
O	2004	2007	for
O	2008	2012	both
O	2013	2017	arms
O	2018	2022	were
O	2023	2030	similar
O	2031	2033	to
O	2034	2039	those
O	2040	2050	previously
O	2051	2059	reported
O	2060	2063	and
O	2064	2072	occurred
O	2073	2086	predominantly
O	2087	2093	during
O	2094	2097	the
O	2098	2107	treatment
O	2108	2114	period
O	2114	2115	.

O	2116	2117	A
O	2118	2131	statistically
O	2132	2143	significant
O	2144	2153	reduction
O	2154	2156	in
O	2157	2160	the
O	2161	2170	incidence
O	2171	2173	of
O	2174	2176	ER
O	2176	2177	-
O	2177	2185	positive
O	2186	2192	breast
O	2193	2199	cancer
O	2200	2203	was
O	2204	2212	observed
O	2213	2215	in
O	2216	2219	the
O	2220	2229	tamoxifen
O	2230	2233	arm
O	2234	2238	that
O	2239	2247	occurred
O	2248	2261	predominantly
O	2262	2268	during
O	2269	2272	the
O	2273	2277	post
O	2278	2287	treatment
O	2288	2294	follow
O	2294	2295	-
O	2295	2297	up
O	2297	2298	,
O	2299	2309	indicating
O	2310	2314	long
O	2314	2315	-
O	2315	2319	term
O	2320	2330	prevention
O	2331	2333	of
O	2334	2342	estrogen
O	2342	2343	-
O	2343	2352	dependent
O	2353	2359	breast
O	2360	2366	cancer
O	2367	2369	by
O	2370	2379	tamoxifen
O	2379	2380	.
